Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Be1116 Prothrombin Complex Concentrate

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

3Total
Phase 3 (3)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04867837Phase 3TerminatedPrimary

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

NCT02281201Phase 3CompletedPrimary

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

NCT00708435Phase 3Completed

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Showing all 3 trials

Research Network

Common Treatments

  • Be1116 Prothrombin Complex Concentrate1
  • Beriplex Pn Kcentra1
  • Fresh Frozen Plasma1
  • Octaplex1

Active Sponsors

  • CSL Behring2
  • Octapharma1
  • Octapharma AG1

Top Investigators

Related Conditions

  • Acute Major Bleeding In Patients Receiving Doac Therapy With Factor Xa Inhibitor1
  • Blood Coagulation Disorders1
  • Reversal Of Coagulopathy1

Activity Timeline